Skip to main content

Advertisement

SpringerLink
Log in

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

  • Research Article
  • Published:
Tumor Biology

Abstract

Emerging evidences have shown that decorin expression is significantly reduced in many cancer tissues and cancer cells. However, its biological role and clinical significance in cholangiocarcinoma development and progression are unknown. In this study, immunohistochemistry was conducted to investigate the expression of decorin in cholangiocarcinomas. The results showed that decorin levels markedly decreased in 44 cholangiocarcinoma tissues compared to 40 adjacent normal tissues. The analysis between decorin expression and clinicopathological characteristics in cholangiocarcinoma patients showed that patients with low levels of decorin expression had a relatively poor prognosis. Moreover, recombinant human decorin treatment and overexpression of decorin in cholangiocarcinoma cells could inhibit cell proliferation, migration, and invasion and promote apoptosis. Furthermore, the E-cadherin expression significantly increased after decorin overexpression or use of recombinant human decorin in cholangiocarcinoma cells. Our findings indicated that downregulation of decorin may be identified as a poor prognostic biomarker in cholangiocarcinomas. Also, decorin-mediated inhibition of cholangiocarcinoma cell growth, migration, and invasion and promotion of cell apoptosis might be through regulation of the expression of E-cadherin in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncol Basel. 2004;66:167–79. doi:10.1159/000077991.

    Article  Google Scholar 

  2. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24:349–56. doi:10.1097/MOG.0b013e3282fbf9b3.

    Article  PubMed  Google Scholar 

  3. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109–14. doi:10.1055/s-2007-1007302.

    Article  CAS  PubMed  Google Scholar 

  4. Nimura Y. Radical surgery: vascular and pancreatic resection for cholangiocarcinoma. HPB (Oxford). 2008;10:183–5. doi:10.1080/13651820801992682.

    Article  CAS  Google Scholar 

  5. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.

    Article  PubMed  Google Scholar 

  6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14. doi:10.1016/S0140-6736(05)67530-7.

    Article  PubMed  Google Scholar 

  7. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78. doi:10.1056/NEJM199910283411807.

    Article  PubMed  Google Scholar 

  8. Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol. 2013. doi:10.1007/s13277-013-0930-9.

    Google Scholar 

  9. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 1999;274:4489–92.

    Article  CAS  PubMed  Google Scholar 

  10. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 2002;19:249–55. doi:10.1023/A:1025383913444.

    Article  CAS  PubMed  Google Scholar 

  11. Hamid AS, Li J, Wang Y, Wu X, Ali HA, Du Z, et al. Recombinant human decorin upregulates p57KIP2 expression in HepG2 hepatoma cell lines. Mol Med Rep. 2013;8:511–6. doi:10.3892/mmr.2013.1510.

    PubMed  Google Scholar 

  12. Toole BP. Solubility of collagen fibrils formed in vitro in the presence of sulphated acid mucopolysaccharide–protein. Nature. 1969;222:872–3.

    Article  CAS  PubMed  Google Scholar 

  13. Stander M, Naumann U, Wick W, Weller M. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 1999;296:221–7.

    Article  CAS  PubMed  Google Scholar 

  14. Bi X, Pohl NM, Qian Z, Yang GR, Gou Y, Guzman G, et al. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis. 2012;33:326–30. doi:10.1093/carcin/bgr293.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A. 1995;92:7016–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res. 2003;9:207–14.

    CAS  PubMed  Google Scholar 

  17. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem. 1996;271:18961–5.

    Article  PubMed  Google Scholar 

  18. Campioni M, Ambrogi V, Pompeo E, Citro G, Castelli M, Spugnini EP, et al. Identification of genes down-regulated during lung cancer progression: a cDNA array study. J Exp Clin Cancer Res. 2008;27:38. doi:10.1186/1756-9966-27-38.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, et al. An antimetastatic role for decorin in breast cancer. Am J Pathol. 2008;173:844–55. doi:10.2353/ajpath.2008.080275.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, et al. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 2008;29:1435–40. doi:10.1093/carcin/bgn141.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Hsu SM, Raine L. Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem. 1981;29:1349–53.

    Article  CAS  PubMed  Google Scholar 

  22. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, et al. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A. 1999;96:3092–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Kresse H, Hausser H, Schonherr E. Small proteoglycans. Experientia. 1993;49:403–16.

    Article  CAS  PubMed  Google Scholar 

  24. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136:729–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol. 1998;141:1277–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, et al. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem. 2005;280:32468–79. doi:10.1074/jbc.M503833200.

    Article  CAS  PubMed  Google Scholar 

  27. Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem. 2005;280:15767–72. doi:10.1074/jbc.M500451200.

    Article  PubMed  Google Scholar 

  28. Guidetti GF, Bartolini B, Bernardi B, Tira ME, Berndt MC, Balduini C, et al. Binding of von Willebrand factor to the small proteoglycan decorin. Febs Lett. 2004;574:95–100. doi:10.1016/j.febslet.2004.08.011.

    Article  CAS  PubMed  Google Scholar 

  29. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66. doi:10.1007/s10555-008-9179-y.

    Article  CAS  PubMed  Google Scholar 

  30. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483–7. doi:10.1126/science.1094291.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996;10:985–96.

    Article  CAS  PubMed  Google Scholar 

  32. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696–701.

    CAS  PubMed  Google Scholar 

  33. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437–49. doi:10.1016/j.ccr.2006.09.013.

    Article  CAS  PubMed  Google Scholar 

  34. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207–35. doi:10.1146/annurev.cellbio.19.011102.111135.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank the National Natural Science Foundation of China (grant nos. 30972910 and 81172269), the Natural Science Foundation of Jiangsu Province (grant no. SBK201123832), the Postdoctoral Science Foundation of China (grant no. 20060390294), and the Key Project Research Fund of Nanjing Medical University (grant no. 2011NJMU246).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Xiaguan District, Nanjing, 210000, China

    Xiang Yu, Quan Li, Yonghuan Mao, Guangming Huang, Xiagang Luo & Chunzhao Yu

  2. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China

    Yanfen Zou & Hui Zhu

  3. Department of Gastroenterology, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Xiaguan District, Nanjing, 210000, China

    Guozhong Ji & Xiuhua Zhang

Authors
  1. Xiang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanfen Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonghuan Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guangming Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guozhong Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiagang Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chunzhao Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiuhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chunzhao Yu or Xiuhua Zhang.

Additional information

Xiang Yu and Yanfen Zou contributed equally to this work and should be regarded as joint first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, X., Zou, Y., Li, Q. et al. Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro. Tumor Biol. 35, 3103–3112 (2014). https://doi.org/10.1007/s13277-013-1402-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1402-y

Keywords

Search

Navigation